LIMERICK, Pa., Mar 10, 2011 (BUSINESS WIRE) --
Teleflex Incorporated (NYSE:TFX), a global provider of medical
technology products, announced today that its Arrow(R) NextStep(TM) Antegrade
Chronic Hemodialysis Catheter has received market clearance from the
U.S. Food and Drug Administration (FDA). The NextStep Antegrade Chronic
Hemodialysis Catheter is designed to attain long-term vascular access
for hemodialysis and apheresis. It is indicated for use in adult
patients. Teleflex expects to launch the product in the United States
later this year.
"The Arrow NextStep Antegrade Catheter is designed to provide some of
the benefits of step-tip and split-tip catheters in a single solution,"
said Benson Smith, Teleflex Chairman, President and CEO. "We are
confident that it will become a preferred option for clinicians who use
the antegrade tunneling procedure to insert chronic hemodialysis
catheters."
The Arrow NextStep Antegrade Chronic Hemodialysis Catheter includes a
step-tip catheter's ease of insertion and a split-tip catheter's
sustained high flow. Compared to traditional chronic hemodialysis
catheters, the ports are reversed to match the heart's natural blood
flow dynamics. The venous port releases blood into the superior vena
cava. The arterial port draws blood from the right atrium. Side holes on
the tip of the catheter are designed to pull blood from all sides of the
catheter. The ports are significantly separated to enhance flow and
minimize recirculation.
The Arrow family of vascular access products includes the ARROWg+ard
Blue PLUS(R) central venous catheters with a
Chlorhexidine-based technology, the recently introduced Arrow EVOLUTION(TM)
PICC with Chlorag+ard(TM) antimicrobial technology and the NextStep
Retrograde, NextStep Antegrade, Edge and Cannon II Plus chronic
hemodialysis catheter product lines. Arrow central venous access
catheters, peripherally inserted central catheters, multi access
catheters and acute hemodialysis catheters are now available in ErgoPack
Maximal Barrier Precautions Trays, a system designed to support
compliance with best practice and guidelines for catheter insertion.
Teleflex also recently expanded its vascular access product offerings
with the acquisition of the VasoNova VPS vascular positioning system, a
central venous catheter tip navigation system.
About Teleflex Incorporated
Teleflex Incorporated is a global provider of medical technology
products that enable healthcare providers to improve patient outcomes,
protect against infections and support patient and provider safety.
Teleflex, which employs approximately 12,500 people worldwide, also has
niche businesses that serve segments of the aerospace and commercial
markets with specialty engineered products. Additional information about
Teleflex can be obtained from the company's website at www.teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
SOURCE: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Vice President Investor Relations
610-948-2836